← Back to Search

NMDA Receptor Antagonist

Arm 1: 0.1 mg/kg ketamine for Acute Pain

Phase 4
Waitlist Available
Research Sponsored by Hackensack Meridian Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 2 hours post infusion completion
Awards & highlights

Study Summary

This study is evaluating whether ketamine is more effective than other dosing strategies for acute pain in the emergency department.

Eligible Conditions
  • Acute Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~within 2 hours post infusion completion
This trial's timeline: 3 weeks for screening, Varies for treatment, and within 2 hours post infusion completion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pain Score
Secondary outcome measures
Adverse Events

Trial Design

3Treatment groups
Active Control
Group I: Arm 1: 0.1 mg/kg ketamineActive Control1 Intervention
0.1 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
Group II: Arm 1: 0.3 mg/kg ketamineActive Control1 Intervention
0.3 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.
Group III: Arm 1: 0.2 mg/kg ketamineActive Control1 Intervention
0.2 mg/kg in a 100 mL solution of dextrose 5% or sodium chloride 0.9% will be give after patient consent and enrollment in the study, vitals are followed (heart rate, systolic blood pressure and respiratory rate) for 2 hours following completion of ketamine infusion. Evaluated for side effects for 2 hours following completion of ketamine infusion.

Find a Location

Who is running the clinical trial?

Hackensack Meridian HealthLead Sponsor
131 Previous Clinical Trials
28,233 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Journal of Anaesthesiology Clinical PharmacologyJournal
Intravenous Sub-anesthetic Ketamine for Perioperative Analgesia
Gorlin, AndrewW, DavidM Rosenfeld, and Harish Ramakrishna. 2016. “Intravenous Sub-anesthetic Ketamine for Perioperative Analgesia”. Journal of Anaesthesiology Clinical Pharmacology. Medknow. doi:10.4103/0970-9185.182085.
Regional Anesthesia and Pain MedicineJournal
Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists
Schwenk, Eric S., Eugene R. Viscusi, Asokumar Buvanendran, Robert W. Hurley, Ajay D. Wasan, Samer Narouze, Anuj Bhatia, Fred N. Davis, William M. Hooten, and Steven P. Cohen. 2018. “Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists”. Regional Anesthesia and Pain Medicine. BMJ. doi:10.1097/aap.0000000000000806.
MMWR. Morbidity and Mortality Weekly ReportJournal
Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014
Rudd, Rose A., Noah Aleshire, Jon E. Zibbell, and R. Matthew Gladden. 2016. “Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014”. MMWR. Morbidity and Mortality Weekly Report. Centers for Disease Control MMWR Office. doi:10.15585/mmwr.mm6450a3.
The American Journal of Emergency MedicineJournal
A Prospective Randomized, Double-dummy Trial Comparing IV Push Low Dose Ketamine to Short Infusion of Low Dose Ketamine for Treatment of Pain in the ED
Motov, Sergey, Mo Mai, Illya Pushkar, Antonios Likourezos, Jefferson Drapkin, Matthew Yasavolian, Jason Brady, Peter Homel, and Christian Fromm. 2017. “A Prospective Randomized, Double-dummy Trial Comparing IV Push Low Dose Ketamine to Short Infusion of Low Dose Ketamine for Treatment of Pain in the ED”. The American Journal of Emergency Medicine. Elsevier BV. doi:10.1016/j.ajem.2017.03.004.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top